BioMarin Acquires Alesta for HPP Pill | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20068532

Show notes

BioMarin just dropped $275 million for Alesta Therapeutics, with another $215 million on the table if things go well — all to grab ALE1, the first oral drug ever for hypophosphatasia, a rare bone disease that’s currently only treatable with injections. This move fits BioMarin’s rare disease strategy and could revolutionize care for thousands of patients — while Alesta spins off its other assets into a new company, keeping its team intact. The deal, funded entirely by BioMarin’s cash reserves, closes in Q3 2026 and marks their third major rare disease acquisition this year. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d4611544c80e2b56

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.